CR10168A - Usos de derivados de heterociclo sulfamida benzofusionados para el tratamiento de epilepsia - Google Patents

Usos de derivados de heterociclo sulfamida benzofusionados para el tratamiento de epilepsia

Info

Publication number
CR10168A
CR10168A CR10168A CR10168A CR10168A CR 10168 A CR10168 A CR 10168A CR 10168 A CR10168 A CR 10168A CR 10168 A CR10168 A CR 10168A CR 10168 A CR10168 A CR 10168A
Authority
CR
Costa Rica
Prior art keywords
epilepsy
sulfamide
derivatives
heterocicle
benzofused
Prior art date
Application number
CR10168A
Other languages
English (en)
Inventor
L Smith-Swintosky Virginia
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CR10168A publication Critical patent/CR10168A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyrane Compounds (AREA)

Abstract

La presente invención es un método para tratar, evitar, revertir, suprimir o inhibir la presentación, desarrollo y maduración de crisis epilépticas o trastornos relacionados con crisis epilépticas; de manera más específica, la presente invención se relaciona con métodos para el uso de derivados de heterociclos sulfamida benzo-fusionados de fórmula (I) y fórmula (II) como se describe en la presente para tratar, evitar, revertir, suprimir o inhibir terapéutica o profilácticamente, epileptogénesis y epilepsia.
CR10168A 2005-12-19 2008-07-21 Usos de derivados de heterociclo sulfamida benzofusionados para el tratamiento de epilepsia CR10168A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75149605P 2005-12-19 2005-12-19
US11/612,174 US20070155824A1 (en) 2005-12-19 2006-12-18 Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis

Publications (1)

Publication Number Publication Date
CR10168A true CR10168A (es) 2009-01-14

Family

ID=38001895

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10168A CR10168A (es) 2005-12-19 2008-07-21 Usos de derivados de heterociclo sulfamida benzofusionados para el tratamiento de epilepsia

Country Status (16)

Country Link
US (2) US20070155824A1 (es)
EP (1) EP1976507B1 (es)
JP (1) JP2009520037A (es)
KR (1) KR101363334B1 (es)
AU (1) AU2006331638B2 (es)
BR (1) BRPI0620017A2 (es)
CA (1) CA2634111A1 (es)
CR (1) CR10168A (es)
EA (1) EA016610B1 (es)
ES (1) ES2392747T3 (es)
IL (1) IL192109A (es)
MY (1) MY147587A (es)
NI (1) NI200800171A (es)
NO (1) NO20083010L (es)
NZ (1) NZ569042A (es)
WO (1) WO2007075834A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
PE20060500A1 (es) * 2004-08-24 2006-07-13 Janssen Pharmaceutica Nv Derivados de heteroaril sulfamida benzo-fusionada como anticonvulsivantes
BRPI0610864A2 (pt) * 2005-05-20 2010-08-03 Janssen Pharmaceutica Nv processo para preparação de derivados de sulfamida
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
AR058389A1 (es) * 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
JP2009537635A (ja) * 2006-05-19 2009-10-29 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 癲癇の処置のための共同−療法
BRPI0822385A2 (pt) * 2008-03-26 2019-09-24 Janssen Pharmaceutica Nv uso de derivados de sulfamida heterocíclicos benzo-fundidos para o tratamento de ansiedade
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
JP2011519839A (ja) * 2008-04-29 2011-07-14 エヌエスエイビー、フィリアル アヴ ノイロサーチ スウェーデン エービー、スヴェーリエ ドーパミン神経伝達のモジュレーター
DK2271638T3 (da) * 2008-04-29 2011-11-28 Nsab Af Neurosearch Sweden Ab Modulatorer af dopaminneurotransmission
WO2009133107A1 (en) * 2008-04-29 2009-11-05 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Modulators of dopamine neurotransmission
PE20110060A1 (es) 2008-06-23 2011-01-31 Janssen Pharmaceutica Nv Forma cristalina de (2s)-(-)-n-(6-cloro-2,3-dihidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US20130253022A1 (en) * 2010-11-30 2013-09-26 Fox Chase Chemical Diversity Center, Inc. Novel fluorinated sulfamides exhibiting neuroprotective action and their method of use
KR20140082762A (ko) 2011-09-29 2014-07-02 얀센 파마슈티카 엔.브이. 설파미드 유도체의 개선된 제조 방법
CA2850513A1 (en) 2011-09-29 2013-04-04 Janssen Pharmaceutica Nv Process for the preparation of sulfamide derivatives
PL2887944T3 (pl) * 2012-08-21 2022-02-21 Sage Therapeutics, Inc. Allopregnanolon do leczenia lekoopornego stanu padaczkowego
CN112041296B (zh) * 2018-04-28 2023-12-29 上海璃道医药科技有限公司 包含苯并含氧脂肪环结构的氨基乙酰胺类化合物及其用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US5212326A (en) * 1979-08-20 1993-05-18 Abbott Laboratories Sodium hydrogen divalproate oligomer
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
GB8908085D0 (en) * 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5229382A (en) * 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5242942A (en) * 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US5258402A (en) * 1992-06-11 1993-11-02 Mcneil-Ppc, Inc. Imidate derivatives of pharmaceutically useful anticonvulsant sulfamates
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5384327A (en) * 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
US5731348A (en) * 1995-02-15 1998-03-24 Bearsden Bio, Inc. Alkylcarboxy amino acids-modulators of the kainate receptor
WO1997019682A1 (en) * 1995-12-01 1997-06-05 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
US5753694A (en) * 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
ES2238999T3 (es) * 1999-02-24 2005-09-16 University Of Cincinnati Uso de derivados de sulfamato para tratar trastornos en el control de los impulsos.
MXPA01010217A (es) * 1999-04-08 2005-09-08 Johnson & Johnson Derivados anticonvulsivos utiles en el tratamiento de trastornos neurodegenerativos cronicos.
US7256184B2 (en) * 2000-10-16 2007-08-14 Rodriguez Victorio C Treatment of aging disorders in humans
US6852738B2 (en) * 2001-01-30 2005-02-08 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
US6949518B1 (en) * 2003-06-25 2005-09-27 Pao-Hsien Chu Methods for treating macular degeneration with topiramate
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
PE20060500A1 (es) * 2004-08-24 2006-07-13 Janssen Pharmaceutica Nv Derivados de heteroaril sulfamida benzo-fusionada como anticonvulsivantes

Also Published As

Publication number Publication date
IL192109A0 (en) 2009-08-03
EA200870094A1 (ru) 2009-02-27
JP2009520037A (ja) 2009-05-21
ES2392747T3 (es) 2012-12-13
EP1976507B1 (en) 2012-09-05
WO2007075834A2 (en) 2007-07-05
AU2006331638B2 (en) 2013-08-22
NZ569042A (en) 2011-04-29
AU2006331638A1 (en) 2007-07-05
HK1125049A1 (en) 2009-07-31
KR20080087827A (ko) 2008-10-01
NO20083010L (no) 2008-09-11
EA016610B1 (ru) 2012-06-29
IL192109A (en) 2014-04-30
NI200800171A (es) 2012-05-28
CA2634111A1 (en) 2007-07-05
WO2007075834A3 (en) 2007-08-16
MY147587A (en) 2012-12-31
BRPI0620017A2 (pt) 2011-10-25
EP1976507A2 (en) 2008-10-08
US20070155824A1 (en) 2007-07-05
US20090209634A1 (en) 2009-08-20
KR101363334B1 (ko) 2014-02-19

Similar Documents

Publication Publication Date Title
NI200800171A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento de la epilepsia
EA201390707A1 (ru) Способ лечения контраст-индуцированной нефропатии
EA201200917A1 (ru) Пролекарства ингибиторов плазменного калликреина
WO2007085019A3 (en) Methods of treating or preventing sinusitis with oxidative reductive potential water solution
PH12013501750A1 (en) Guanidine compound
DOP2010000381A (es) Compuesto heterociclico y su uso
EA201390794A1 (ru) Бициклическое соединение
WO2006042150A8 (en) Diaminoalkane aspartic protease inhibitors
WO2006124913A3 (en) Compositions and methods for the treatment of disorders of the central and peripheral nervous systems
NZ601350A (en) Method of treating arthritis
ATE458485T1 (de) Ubiquitin-ligase-hemmer und verwandte verfahren
IL192103A0 (en) Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
AR063724A1 (es) Metodo de purificacion de aceite y sus usos para alimentos para personas y alimentos para animales
AR061067A1 (es) Coterapeutica para el tratamiento de epilepsia y trastornos relacionados
WO2007095608A3 (en) Use of benzo-heteroaryl sulfamide derivatives for the treatment of disease modification of epileptogenesis
WO2008073332A3 (en) Creatine compositions for skin treatment
WO2013177349A3 (en) Quinazolinediones as tankyrase inhibitors
MX2009011068A (es) Agentes anti-angiogenicos y metodos de utilizacion.
ECSP10010498A (es) Procesos para la preparación de derivados de heteroarilo benzofusionados
CR11761A (es) Proceso para la preparacion de sulfamatos de heteroarilo benzofusionado y la forma cristalina de n-(((2s)-6-cloro-2,3-dihidro-1,4-benzodioxin-2il)metil-sulfamida
AR061898A1 (es) Procesos para correlacionar los espectros uv-vis del compuesto norborneno para los procesos de polimerizacion utilizando los mismos y los metodos y las composiciones de purificacion relacionados
MX2012007142A (es) Uso de 2,3-dihidroxipropil dodecanoato para tratar seborrea.
MD20070287A (en) Process for purifying effluent in anaerobic reactor
WO2008009634A3 (en) Factor viia analogues with increased activity for treating thrombocytopenia
ATE551052T1 (de) Verwendung von reninhemmern zur prävention oder behandlung von diastolischer dysfunktion oder diastolischer herzinsuffizienz

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)